Pulmonary Embolism 101 with Parth Rali, MD


In the latest episode of Lungcast, the diagnosis, classifciation and treatment of PE—namely blood clots—is comprehensively dissected by the Lewis Katz School of Medicine clinician and investigator.

Episode highlights

0:16 Intro
2:34 Defining pulmonary embolism classifications
8:18 The Pulmonary Embolism Severity Index
15:47 The role of D-dimer in diagnosis
17:08 Anticoagulation strategies
22:26 The Pulmonary Embolism Multidisciplinary Response Team
25:38 Long-term outlooks for acute PE
31:38 When to stop anticoagulation
35:27 The future of PE diagnosis and treatment
38:50 Outro

The third most common cause of death among hospitalized patients, pulmonary embolism (PE) is a well-understood threat among pulmonologists and emergency specialists alike. That doesn’t change the fact the commonly lethal condition is potentially lesser understood by would-be patients—and its undercurrent of diagnostic and treatment strategies are not fully appreciated by health care providers.

In the latest episode of Lungcast, PE—namely blood clots—is comprehensively dissected as a component of pulmonary disease management.

Parth Rali, MD, associate professor of thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University, joins show host Albert Rizzo, MD, American Lung Association (ALA) chief medical officer, for a review of PE classification and diagnostics, anticoagulation treatment paradigms, and long-term outlooks in patients with PE.

Along the way, the pair additionally discuss the emerging multidisciplinary care team that represents modern optimal PE outcomes, the current and future utility of numerous tools in diagnostics including artificial intelligence, and the means by which PE is graded and monitored in impacted patients.

Lungcast is a monthly respiratory health podcast series from the ALA produced by HCPLive.

Subscribe to Lungcast on Spotify here or listen to the latest episode below:

Related Videos
Brendon Neuen, MBBS, PhD | Credit: X.com
A Promising Pipeline for COPD
Projecting Dupilumab's Fit in COPD
What the Ensifentrine FDA Approval Means for COPD
A panel of 5 cardiovascular experts
Pavel Strnad, MD | Credit: RWTH Aachen
Video 5 - "Real-World Insights: Navigating Cardiac Myosin inhibitors in Practice" - Featuring 1 KOL
A panel of 5 cardiovascular experts
A panel of 5 cardiovascular experts
Video 4 - "Mavacamten in oHCM: Navigating the REMS Program for Safe, Optimal Outcomes "
© 2024 MJH Life Sciences

All rights reserved.